Anavex Life Sciences Corp (AVXL)

[XenaLives]

Compiled Due Diligence 07/17/19


Comment:More updates coming soon but I wanted the shelf info to be visible.
__________________________________________________________________________________________________
Comments to put the shelf offering in perspective:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149743089
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149743702
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149748255
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149780479
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149784662
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149788415
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149801350

General analysis of S-3 filings -
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149784281

Link to Annual Report:
https://www.sec.gov/Archives/edgar/data/1314052/000161577418014328/0001615774-18-014328-index.htm
https://www.sec.gov/Archives/edgar/data/1314052/000161577418014328/s114606_10k.htm
Link to all SEC filings:
https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001314052&action=getcompany
Link to Pipeline graphic: https://www.sec.gov/Archives/edgar/data/1314052/000161577418014328/img001_v1.jpg
Mouse PET images: https://www.sec.gov/Archives/edgar/data/1314052/000161577418014328/img002_v1.jpg

PIPELINE


Evolution of the pipeline:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147064606

Results of 4/5/19 shareholder vote:
https://www.sec.gov/Archives/edgar/data/1314052/000161577419005452/s117292_8k.htm

Shareholder rights plan:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145724043

Company website - upcoming and past events:
https://www.anavex.com/investor-material/events/

Company Website - presentations on line:
https://www.anavex.com/investor-material/

Transcript of 12/12/18 Conference call:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145435190

Access to 12/18 Conference call:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145347046

Quick link to SEC filings:
https://fintel.io/filings/us/avxl

Link to SEC filings on EDGAR:
https://www.sec.gov/cgi-bin/browse-edgar?CIK=avxl&owner=exclude&action=getcompany
__________________________________________________________________________________________________
SHAREHOLDER'S MEETING NOTES:

Discussion of shareholder's meeting 04/05/19 begins here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148045215

Thanks to our MB, on the scene reporters...
brichnyc, bourbon, and Jonjones325

From bourbon_on_my_cornflakes:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148047383
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148050828
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148058557

From Jonjones325:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148057082
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148057307

From brichnyc:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148084098
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148086244

__________________________________________________________________________________________________
UPCOMING PRESENTATIONS, OTHER POSSIBLE EVENTS:

Dr. Harald Hampel and this years upcoming AAIC meeting
Possibly related to Anavex (from georgejjl)

Combining Omics and Imaging Data from the Insight Pre-AD Study, Artificial Intelligence Technology Identifies Genomic Biomarkers for Early Detection of Alzheimer’s Disease
515 AB
O5-07-04
12:30pm - 12:45pm
Thu, Jul 18

Combining Omics and Cognitive Tests Data from the Insight Pre-AD Study, Artificial Intelligence Technology Identifies Genomic Biomarkers for Early Detection of Alzheimer’s Disease
515 AB
O2-05-02
2:15pm - 2:30pm
Mon, Jul 15

Anavex is returning to the 2nd Annual Neuropsychiatric Drug Development Summit from July 23-25 in Boston.

On July 23, Dr. Missling will lead 1 of 3 pre-conference workshops; Reviewing the Potential for Precision Medicine in Neurological Diseases.

On July 25, he will also be featured in a 2-person panel with Sean Smith, the Executive Director of Neuroscience Discovery at Merck; Panel Discussion: The Precision Medicine Approach to Neuropsychiatry – For or Against?

Download the Full Event Guide at the website below for further details:
https://npd-summit.com/
Original from TTAV66:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147736866

SVP of Operations, Stephan Toutain, will host a roundtable discussion on "Market Access and Comercialization" at the 11th Orphan Drugs and Rare Diseases Global Congress in Boston on Sept. 11, 2019.(contributed by TTTav66):
https://www.orphandrugsus.com/

16th international conference on Dementia and Alzheimer Disease
February 10-11, 2020 Sydney, Australia (from georgejjl)
https://dementia.annualcongress.com/events-list/parkinson-s-disease

Possible Catalysts
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145908635
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148107153
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149157245

We are still awaiting Dr Kaufmann's presentation on gut microbiome data. (from kevli33)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148871706
__________________________________________________________________________________________________
RECENT PRESENTATIONS:

Roth panel discussion "Rise and Fall of Amyloid" 3/19:
http://wsw.com/webcast/roth33/panel22/?lobby=true&day=2

A closer look at the Roth Capital Partners Conference Alz panel that Dr Missling is part of (Beyond the Rise and Fall of Amyloid) - (from makemydaze)
https://www.meetmax.com/upload/event_51941/ROTH_2019_Healthcare_Marango_Panel.pdf

Anavex Life Sciences at the Cowen 39th Annual Health Care Conference 2019 Wednesday, March 13
http://wsw.com/webcast/cowen52/avxl/. A replay will be available via www.anavex.com and will be accessible for three months following the presentation.

Feb. 11-12 : BIO CEO & Investor Conference
Presentation
https://www.veracast.com/webcasts/bio/ceoinvestor2019/78204240532.cfm?0.22201266802
Slides only
https://www.anavex.com/wp-content/uploads/2019/02/Anavex-BIO-CEO-Feb-2019-1.pdf

Missling interview:

Walter E. Kaufmann
Until recently, he was the Director of the Center for Translational Research at the Greenwood Genetic Center, where he also held the Ravenel Boykin Curry Chair in Genetic Therapeutics. Now he is the Anavex CMO. (originally posted by kevli33)

__________________________________________________________________________________________________
AUDIO PRESENTATIONS:

Cantor Fitzgerald Presentation from Cantor Fitzgerald Global Healthcare Conference October 3, 2018 2:50 p.m.
http://wsw.com/webcast/cantor7/avxl/

Comment on the above from dia76ca "At Cantor Dr. Missing said that the Rett trial would "clear VERY SOON"(At the 27:30 minute mark). We would do well to remember some of the other things he said.(e.g. Cash on hand for 2 years...21:21 minute mark ; Anavex 3-71 in clinic in 2019...29:34 minute mark ; Parkinson read-out in 2019...30:40 minute mark."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144349470

Additional audio presentations on the company web site see links at top of post.
__________________________________________________________________________________________________
VIDEO PRESENTATIONS

Dr. Harald Hampel, MD, PhD, MA, MSc: Genomic Analysis of ANAVEX 2-73 in Alzheimer Disease Study 10/18, Videos:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148601340

Anavex SAB member Dr Paul Aisen speaks about PET Scans:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143921781

History of rettsyndrome.org featuring Christopher Missling:

Dr. Tangui Maurice on the Sigma 1 - 2015 video:(from kevli33)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143980208

SAB member Jacquelin French, videos discussing Seizures and Epilepsy: (from kevli33)

Videos from UC and Rob Knight (not Anavex specific, but cutting edge science.)
Microbiomes and aging:

Microbiome mind and brain interaction:
https://www.youtube.com/watch?v=2iKHMyWzclM&t=134s
All of Rob Knight's videos are interesting:
https://www.youtube.com/results?search_query=rob+knight

Dementia risk and blood pressure from kevli33:

The Emerging Antimicrobial Protection Hypothesis of Alzheimer's Disease (from kevli33)

Macfarlane on medication in dementia:

Additional video presentations on the company web site see links at top of post.


__________________________________________________________________________________________________
SLIDE SHOWS AND POSTERS:

From TTTav: October Corporate Presentation used at the Cantor Fitzgerald Conference
https://www.anavex.com/wp-content/uploads/2018/10/Anavex-Presentation-Oct-2018.pdf

Dr Robert Lisak’s MS poster presented at the 2018 ECTRIMS conference:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144223191&txt2find=ectrims

Anavex 2-73 as a potential treatment for autism spectrum disorders 2016
https://anavex.com/wp-content/uploads/2016-06-06_Poster_AV2-73_Autism_FXS_Conference_June_2016.pdf

Kaufmann presentation 3/27/19
American Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting
https://www.anavex.com/wp-content/uploads/2019/03/Anavex-ASENT-March-2019.pdf

https://www.anavex.com/wp-content/uploads/2019/03/Anavex-Presentation-March-2019-1.pdf

Titration could increase the response and efficacy of Anavex 2-73.
A plasma concentration of greater than 4 ng/ml would increase postive responses and efficacy to Anavex 2-73 (from georgejjl)

Slide 10
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147511076

From Slide 27:

Value-Creating Catalysts – Clinical updates from Phase 2 Parkinson’s disease dementia study, Phase 2b/3 Alzheimer’s disease and Phase 2 Rett syndrome studies anticipated in 2019. Clinical datapublications and additional indications to be announced in 2019.

What is Actigraphy Monitoring? Mentioned in 3/19 Missling presentation. (from nidan7500)
https://www.verywellhealth.com/what-is-actigraphy-3015130
https://www.actigraphcorp.com/

CTAD 2018 slides - see the following archive
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146087872

__________________________________________________________________________________________________
POSSIBLE SIGNS OF MOVE TOWARD COMMERCIALIZATION:

Does 2-73 have a name?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146539861
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146540287
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146540557
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146545746

Info on why Anavex needed to spend $1 million on product development in 2018. (from ohsaycanyousee82)
http://www.pharmtech.com/api-sourcing
Discussion of above follows this post:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146733092

__________________________________________________________________________________________________
GENERAL TRIAL DISCUSSION AND COMMENTS ON TRIAL PROCEDURE:

These discussions are moved to the "OTHER COUNTRIES - General Coments" post, see the links at the end.

__________________________________________________________________________________________________
BIOMARKER DISCUSSIONS:

New Markers For Alzheimer's Disease Could Aid Diagnosis And Speed Up Drug Development (from maverick_1)
https://www.npr.org/sections/health-shots/2019/07/04/738478841/new-markers-for-alzheimers-disease-could-aid-diagnosis-and-speed-up-drug-develop

The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149674738

Alzheimer's eye test to enter trial phase in hopes of diagnosing before symptoms appear
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149163374

Cbdpotential on systems and reference to a 2017 paper by Harald Hampel:

A Precision Medicine Initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149737160

Discussion on 4/25/19 concerning new blood tests for Alzheimer's - read forward from here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148425843

Alzheimer's biomarkers explained:
https://www.alzdiscovery.org/news-room/blog/alzheimers-biomarkers-explained

On Biomarkers and Surrogate Endpoints. A read forward into the discussion is suggested for additional information on sleep and Alzheimer's:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145241236
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145245388
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145245674
(several posts follow the last link)

Current state of Alzheimer's fluid biomarkers. - Full Paper (from Investor2014)
https://link.springer.com/article/10.1007/s00401-018-1932-x
More on AD and sleep...as predicted... (from nidan7500)
https://alzheimersnewstoday.com/2019/03/15/brains-of-people-with-sleep-apnea-show-higher-burden-of-tau-protein-aggregates

Did ACTC consider new biomarkers for this Eisai study?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148730321

Possible approval based on sleep, with ERP/EEG taken as suporting biomarker evidence
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148919365
_______________________________________________________________________________________________________________
ALZHEIMER'S DISCUSSIONS :

The economiic impact of dementia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148593001

Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease (from kevli33)
https://www.alzheimersanddementia.com/article/S1552-5260(19)30077-9/fulltext

"Our paper on plasma amyloid beat 40/42 ration predicts cerebral amyloidosis in asymptomatic at risk individuals for AD has been published in Alzheimer's & Dementia"(from kevli33 quoting Harald Hampel tweet)
https://goo.gl/scholar/JZH7Zw

Commonly prescribed drugs are tied to nearly 50% higher dementia risk in older adults, study says (from kevli33).
https://www.cnn.com/2019/06/24/health/dementia-risk-drug-study/index.html

HIGH CHOLESTEROL LINKED TO ALZHEIMER'S DISEASE (from kevli33)
https://www.newsweek.com/high-cholesterol-linked-alzheimers-disease-1437215

Blood pressure and dementia study with a good video:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149079241

March 2019 discussion of ACTC begins here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147409548

Comparison of published A2-73 AZ 57wk data to current AZ trial (from TempePhil)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148859931

The Alzheimer Precision Medicine Initiative Journal of Alzheimer's disease:
https://content.iospress.com/articles/journal-of-alzheimers-disease/jad181121

Improved Diagnostic for Alzheimer's - just perfect for Anavex 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148616412

TempePhil analysis of corporate presentations, possible 208 wk data:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148154210

Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/ CTAD Task Force (from Kevli33)
https://www.ctad-alzheimer.com/files/files/Anti-Tau%20trials%20for%20AD%20-%20A%20report%20from%20the%20EU%20US%20CTAD%20Task%20Force.pdf

Basic biology concepts for Alzheimer’s disease
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137348423

The company's stated timeline for Alzheimer's P2b/3:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144956279

Missling states that PET scans will be used in P2/3 trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143981335

P2b/3 dosage slide:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145842885

Blood concentration seems to be important:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147596397

On titration of 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147635325
Possible partnering for Alzheimer's diagnosis and treatment protocol from tredenwater2
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145766313

U.S. Alzheimer's diagnosis is inferior:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148065564
Will it take 48 weeks to realize these endpoints?
https://investorshub.advfn.com/boards/read_msgs.aspx?board_id=11474&NextStart=178123&BatchSize=20

Possible causes of Alzheimer's summarized:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146243514

Discussion of P2a trial dropouts:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144496759

Missling 2017 comment on blood concentration (from georgejjl):
https://www.mdedge.com/clinicalneurologynews/article/152595/alzheimers-cognition/development-sigma-1-receptor-agonist

Fluoride and Alzheimer's
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147640105

What does Donepezil do?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144744473

How does the body handle Donepezil?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145773592

On the difficulty in diagnosing Alzheimer's:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145129244

Stresses on Caregivers:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147069410

Alzheimer's specific sleep scale:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144847354&txt2find=caregivers

Vitamin D and Alzheimer's:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145586595

AI used to detect Alzheimer's in PET scans (from baltimorebullet)
https://kottke.org/19/01/ai-algorithm-can-detect-alzheimers-earlier-than-doctors

More on Amyloid PET AD diagnostics from Hampel tweet.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146598748

Paper on progression from MCI to Alzhimer's posted by Investor2014 (includes sleep)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762666/

Apoe4 and Alzheimer's
https://medicalxpress.com/news/2016-08-scientists-reveal-people-apoe4-gene.html
https://www.snpedia.com/index.php/APOE

African Americans and Alzheimer's
https://investorshub.advfn.com/boards/read_msgs.aspx?board_id=11474&NextStart=177836&BatchSize=20

French healthcare system decides it will no longer reimburse for Donepezil and other Alzheimer's drugs.
http://english.prescrire.org/en/81/168/55126/0/NewsDetails.aspx

Alzheimer's & SOC - too many patients exposed to drug interactions: French data:
http://english.prescrire.org/en/81/168/49338/0/NewsDetails.aspx

Macfarlane and Hammond Care CEO Stephen Judd on overmedication of elderly patients:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146079150

Could Disposing of Damaged Mitochondria Treat Alzheimer’s Disease? (from Investor2014)
https://www.alzforum.org/news/research-news/could-disposing-damaged-mitochondria-treat-alzheimers-disease

Do we have a good chance to win in the "Oskar Fischer Project" ?
https://alzheimersnewstoday.com/2018/11/09/new-challenge-offers-prize-money-better-understanding-alzheimers/

Might Anavex-facilitated Sleep Prevent Alzheimer’s? (from Falconer66a)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147042424

P300 Amplitude Discussion: See IP section and Partners section

See also insomnia patent under IP, sleep section, and more in ERP in partners section.
Links at the end of this post

__________________________________________________________________________________________________
PARKINSON'S DEMENTIA DISCUSSIONS :

Trial listing Parkinson's on clinicaltrials.gov as of 12/13/18
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145772074
How the Parkinson's Dementia trial may help expedite Alzheimer's approval:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143580569

Announcement of Aussie PDD trial
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148578140

Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways (from georgejjl)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373401/

Listing of Spanish PDD trial sites:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149316525

Aussie PDD trial will evaluate sleep:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148934406

Scientists Are Warning of a Future Parkinson's Pandemic, And We Can't Ignore It (from Amateur17)
https://www.sciencealert.com/research-warns-of-a-pending-parkinson-s-pandemic-and-we-need-to-pay-attention

Parkinson's News Today announces trial with participation of MJF foundation from whippensaw:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144653898

Sokol on how 2-73 benefits PDD patients:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149155921

** EU and Spanish Trial **

EU Parkinson's trial info:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144654071

Spanish trial info:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144654240

Spanish info on Parkinson's trial as of 2/26/19
http://www.gacetamedica.com/especializada/comienza-la-segunda-fase-del-estudio-clinico-para-enfermedad-de-parkinson-con-demencia-asociada-MG1945349
English Translation:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147248343

Spanish publication mentioning Anavex PDD trial
https://issuu.com/parkinsonmadrid/docs/revista_70_issue/1?ff

From K9uwa aka John: Today in Parkinsons News Today ENROLLING NOW in Spain article.
http://parkinsonsnewstoday.com/2018/11/01/anavex-recruiting-parkinsons-dementia-patients-spain-anavex-2-73-trial/

Parkinson's researchers have asked for an extension:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147933240
http://wsw.com/webcast/cowen52/avxl/

Parkinson's endpoints cognition and motion
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145688901
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145689920

Spanish info on Parkinson's trial as of 2/26/19
http://www.gacetamedica.com/especializada/comienza-la-segunda-fase-del-estudio-clinico-para-enfermedad-de-parkinson-con-demencia-asociada-MG1945349
English Translation:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147248343

** Australian Trial **

January 19 AU governement allocated an additional $36.8 million for Parkinson's research.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148593663

Hammond Care to join in Parkinson's Dementia trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148578140

Australia has a 5 year plan for Parkinson's
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148988597

Hammond Care to join in Parkinson's Dementia trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148578140


** Sleep, Science, and PDD **

New Sensor Technology Can Detect Medication Response Automatically for Parkinson’s Disease Patients
https://patientworthy.com/2019/04/24/sensor-technology-detect-response-parkinsons-disease-pd/

Sleep in Parkinson's disease -
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145233486

Biostockclub on Parkinson's dosage:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144533102

More on Parkinson's and sleep (from nidan7500):
https://parkinsonsnewstoday.com/2019/03/13/study-factors-sleep-benefit-parkinsons-disease/

Apathy and Depression Linked to Sleep Disorder in Parkinson’s Patients, Study Finds
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148336025

Testing method to be used:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145428524

Dr. M. Angela Cenci Nilsson resulting study from the 2015 research grant
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148339012
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148342120
PROFILE
http://www.academia-net.org/profil/prof-dr-m-angela-cenci-nilsson/1488381

Veronica Francardo
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148342376
Francardo May 2018 statement on effect of 2-73 in Parkinson's
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134044839

Anavex PR's from the Lund preclinical research on Parkinson's by Cenci-Nilsson and Francardo.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148343391

__________________________________________________________________________________________________
RETT SYNDROME DISCUSSION :

Video of Rett Syndrome Kids (from kevli 33)

From the principle investigator of AVATAR: (and kevli33)
https://www.neurologylive.com/clinical-focus/automated-epilepsy-diagnostic-monitoring-systems-effective
http://ccsmonash.blogspot.com/2017/06/welcome-to-professor-terry-obrien-new.html
https://www.researchgate.net/profile/Terence_OBrien

Professor Terry O'Brien running Rett trial at Alfred Health
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149294128
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149294230

Link to Herald Sun article on AVXL Alzheimer's and Rett trials, posted by TTav66
https://www.pressreader.com/australia/herald-sun/20190607/281655371571373

June 7 Pr on the Rett trial, mentions fast track:
https://investorshub.advfn.com/boards/readmsg.aspx?message_id=149293556

Rett Syndrome: A Focus on Gut Microbiota. (from georgejjl)
An important read
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343879/

Australian Rett Syndrom Trial starts May 9 2019 (from Greenspam3)
https://www.facebook.com/rettaustralia/
https://www.anavex.com/rett-syndrome-association-of-australia-and-anavex-life-sciences-announce-initiation-of-the-phase-2-avatar-clinical-study-in-patients-with-rett-syndrome/

On Missling's plan for Rett Trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148732543

"RettSyndrome.org updated their Clinical Trials information on 4/4/19 with the link below.
This will give the Rett Families a bit more information and encourage trial participation."
(Quoted and provided by Talon38)
https://www.rettsyndrome.org/file/press-releases/Anavex-doses-1st-Patient.pdf

Trial listing Rett Syndrome on clinicaltrials.gov as of 12/07/18
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145772107

Rett Syndrome prospects, trial update, and patent (from georgejjl )
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146683698
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146684425
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146720630

ANAVEX 2-73 Normalizes Hippocampal BDNF Expression
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148132992

For the first time a human disease — Rett Syndrome, the first identified epigenetic disease — has been linked to specific defects in the three-dimensional folding of chromatin. (from georgejjl)
https://www2.lbl.gov/Science-Articles/Archive/LSD-Rett-syndrome.html
see also:
https://www2.lbl.gov/Science-Articles/Archive/assets/images/2004/Dec-20/DLX5-Rett-Syndrome.pdf

Epigenomics and Rett Syndrome:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147643763

On the ambiguity in earnings call on Rett trials:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146678488
Response from runcoach:
https://investorshub.advfn.com/boards/replies.aspx?msg=146678488

FDA Revising ‘Draft Guidance’ on Developing Treatments for Rare Diseases (from nidan7500)
https://rettsyndromenews.com/2019/01/30/fda-revising-draft-guidance-on-developing-treatments-for-rare-diseases/
Levetiracetam possible for Alzheimer's
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147247821

Anavex 2-73 synergism with levetiracetam for treatment of Rett syndrome and epilepsy.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147246715

Rett syndrome testing via auditory event:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146263432

Rettsyndromenews.com on the 2-73 trial
https://rettsyndromenews.com/2019/01/08/phase-2-trial-anavex-2-73-rett-syndrome/

Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett Syndrome
Study will incorporate genomic precision medicine ANAVEX®2-73-specific biomarkers
https://www.anavex.com/anavex-life-sciences-announces-fda-approval-of-ind-for-phase-2-trial-of-anavex2-73-in-patients-with-rett-syndrome/

Rett Syndrome trial and endpoints announced on Clinicaltrials.gov 11/29/18 (Thanks to poster Abel and Cabel)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145164109

Info on Dr. Kaufmann who will be running the 2-73 Rett Syndrome trial and who is now CMO for Anavex:
http://gcbcenter.kennedykrieger.org/staff.jsp

2016 presentation on Rett Syndrome
https://anavex.com//wp-content/uploads/ANAVEX-2-73-as-a-Potential-Treatment-for-Rett-Syndrome.pdf

2017 presentation on Rett Syndrome

Rett Syndrome in adults:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145216562
http://www.anavex.com/wp-content/uploads/2017/05/Anavex-Angelman-FX-Rett-conference-update-2017-May-2017-final.pdf

Rett Syndrome & Fragile x - they are are related:
From Talon38 (post 173314) "NIH's updated (2 days ago) information on Fragile X. Notice both the similarities and differences (predominantly a male diseases). Fragile X is one of 2-73's pipeline targets as is Infantile Spasms and Angelman's. Not a stretch to believe that Tayo Fadiran has been working CDER and NIH for a combined clinical trial to these orphan diseases. With positive Rett Syndrome results, that may come to fruition. The 2-73 "train" is gathering momentum!"
https://ghr.nlm.nih.gov/condition/fragile-x-syndrome

Rett Syndrome Study Design a link Natural History Study Publications from Investor2014:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144701675
https://www.rettsyndrome.org/for-researchers/nhs-research-publications

Discussion of Rett Trial Design why it is structured the way it is:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144356675
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205166

On the disease phases of Rett Syndrome:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144701046

Will the trial be moved to Australia?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144362026

On Rett Syndrome and the M4 Receptor from Investor2014:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144347886

Other Rett Syndrome related posts:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144357506
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135703149

Disturbed redox homeostasis and oxidative stress: Potential players in the developmental regression in Rett syndrome
https://www.sciencedirect.com/science/article/pii/S0149763418306900 (from Investor2014)

Talon38 provided this NIH link on Rett Syndrome:
https://ghr.nlm.nih.gov/condition/rett-syndrome

dadofmarcmax on Rett Syndrome and other epileptic diseases:
see CNS ADDITiONAL INDICATIONS below

Paper on Rett Syndrome treatment procedures:
https://pdfs.semanticscholar.org/c2c8/1063888a7aecffd3b1fe74a7b67496b2554f.pdf
__________________________________________________________________________________________________
EPILEPSY DISCUSSION:

Question of Epilepsy parnership:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147238816

PennyDouble reminds us, we have an expert on the SAB :
https://www.anavex.com/anavex-life-sciences-appoints-distinguished-researcher-neurology-epilepsy-scientific-advisory-board/

The significance of adding Dr Andrew Cole MD authority on Epilepsy to Anavex SAB:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144358640
__________________________________________________________________________________________________
FRAGILE X DISCUSSION:

Fragile X syndrome connected to mitochondrial dysfunction. (from Steady_T)
https://medicalxpress.com/news/2019-02-cell-component-breakdown-treatment-multiple.html

Fragile X is a growing concern (link from cninc):
https://www.frontiersin.org/articles/10.3389/fpsyt.2018.00564/full
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144971728

Will fragile x start trials soon?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146687514

Anavex 2-73 and the autism market:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147237001&txt2find=2016

Kaufmann paper on FragileX and Autism:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148178337

Autism and sleep...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149039440

Facts about autism spectrum disorder:(from georgejjl)
http://www.autism-society.org/what-is/facts-and-statistics/
__________________________________________________________________________________________________
MULTIPLE SCLEROSIS DISCUSSION:

Dr Lisak's preclinical of 2-73 in MS:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147244571

MS - needs more scientific development in order to support a successful 2-73 trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145845309
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145855079

Youtubes on Myelin:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145846058

MS is still on the table per 12/12/18 10K
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146069570

MS and gender bias
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145789105

Anavex - Biogen & MS
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135630393
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143729928
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143732818
https://investorshubAL.advfn.com/boards/read_msg.aspx?message_id=143734046
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144040837
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143735763
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147244426

__________________________________________________________________________________________________
SCHIZOPHRENIA DISCUSSION :

Crosstalk between endoplasmic reticulum stress and oxidative stress in schizophrenia: The dawn of new therapeutic approaches.
(link from georgejjl)
https://www.ncbi.nlm.nih.gov/pubmed/28890198
see also:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461562/

__________________________________________________________________________________________________
OTHER CNS & ADDITIONAL INDICATIONS:

Opportunities for treatment with Anavex 2-73 and/or Anavex 3-71

Image from AVXL presentation, clipped by georgejjl

From dadofmarcmax, the linked site has TONS of info:
"Why does Anavex 2-73 have effects on seemingly different neuro-degenerative disorders? What makes it so special? "
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143816865

CADASIL - Notch3 gene mutation
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148872809
https://investorshub.advfn.com/boards/replies.aspx?msg=148872809

Falconer on commonalities of CNS disease:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145055598

Anavex 2-73 and/or 3-71 as a treatment for postpartum depression
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144995494&txt2find=71

A2-73 mixed S1R and Muscarinic modulation - not just S1R. (from Investor2014)
Citation from this paper: https://www.google.co.uk/amp/s/www.researchgate.net/publication/11175896_AF150S_and_AF267B_-_M1_muscarinic_agonists_as_innovative_therapies_for_Alzheimer's_disease/amp

Alzheimer’s and Parkinson’s Disease: Similarities and Differences (Aarsland and Weintraub have AVXL affiliation)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147932208

Autophagy and mitophagy in ALS.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147418161

Angelman Syndrome:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147200990

Protein Misfolding and ER Stress in Huntington's Disease (from georgejjl)
https://www.frontiersin.org/articles/10.3389/fmolb.2019.00020/full

dadofmarcmax on treatment of epilepsy with Anavex platform drugs:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=127872231
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=131111781
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144438361
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135019599
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135028269

A2-73 for macular degeneration
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148342276

Huntington's Disease and aging mitochondria:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145684759
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145684899
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145685427

Diabetic market:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145572335

Psychiatric disease:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145559580

Normalization of hypertension - peer reviewed in January 2018
https://www.anavex.com/anavex-life-sciences-reports-potential-normalization-of-hypertension-with-anavex2-73-published-in-the-journal-of-clinical-hypertension/

Causes of CVD, mitochondrial dysfunction, oxidative stress and neuroinflamation:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146829394

Anavex 2-73 and/or Anavex 3-71 could be used to treat TBI Traumatic Brain Injury
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145739701
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147181730

Anavex also has Orphan Drug Designation for Infantile Spasms:
https://www.anavex.com/anavex-announces-u-s-fda-orphan-drug-designation-for-anavex-2-73-for-treatment-of-infantile-spasms/

The emerging roles of protein homeostasis-governing pathways in Alzheimer's disease.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147703240

__________________________________________________________________________________________________
MISC. DISCUSSIONS:


Mayo Clinic researcher states that the P2a improved cognition and function:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149549864

Systems theory and systems biology paradigms bio
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149449161

Neurodevelopment in children:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143439222

The U.S. has a "national mental health epidemic. The damage is on the scale of the global financial crisis." (from Lima4918)
https://www.bloomberg.com/news/articles/2019-06-20/latest-suicide-data-show-the-depth-of-u-s-mental-health-crisis?srnd=premium

Rising to the Challenge: Developing New Medicines for Rare Disease (from kevli33)
https://checkrare.com/rising-to-the-challenge-developing-new-medicines-for-rare-disease/

Falconer taking the temperature of the medical research community:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148589256

2015 mention of ERP results at five weeks:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148130307

Anavex 2-73 might show better results with younger patients than older patients.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148058285

2015 new discovery about the brain and the immune system:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148062119

“Enabling precision medicine with integrated genomic and clinical data” posted by Harald Hampel and kevli33
https://twitter.com/harald_hampel/status/1114590967531753472?s=21
https://azure.microsoft.com/en-us/blog/enabling-precision-medicine-with-integrated-genomic-and-clinical-data/

Anavex is not just a drug company - opinion from Lima4918
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147759921

Old brains and neurogenesis (from powerwalker).
https://www.statnews.com/2019/03/25/old-brains-make-new-neurons-possibly-protecting-against-alzheimers/

Top 20 CNS drug companies:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147869585

A new urgency for Expanded Access:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147906853

An excellent summary of why we are here from poster sokol:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143320176

Sokol on Anavex's international strategies:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144504285

Link to PeterKarol's blog:
https://piotrpeterblog.com/

Scientists rise up against statistical significance (from Biostockclub)
https://www.nature.com/articles/d41586-019-00857-9

Life expectancy in the US still continues to go down, 2018 graphic:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147424525

Short term milestone summary:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144330988

Comment on industry trends (link from PennyDouble)
https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/us-and-global-life-sciences-industry-trends-outlook.html

Protein degradation disease treatments:
https://www.investors.com/news/technology/protein-degradation-eyed-pharmaceutical-companies-drug-development/

AI estimates brain age:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147255249

Orphan Disease Designation in Rett and Infantile Spasm
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146540508

Expansion of rare disease diagnostic codes (from nidan7500)
https://dravetsyndromenews.com/2019/02/04/icd-10-codes-really-important-to-rare-disease-patients-soon-up-for-fresh-consideration/

Missling has a strategy - comments from posters on that strategy:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144051610
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144350599
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145164402

Personal comments from falconer66a on the failure of traditional western medicine:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144979916

How the U.S. is failing its people in healthcare:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145076878

Brain cells from stem cells at Lund University:
https://www.lunduniversity.lu.se/article/new-method-grows-brain-cells-from-stem-cells-quickly-and-efficiently

Sokol with a 2016 perspective on potential Alzheimer's treatments:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144809093

2018 Shareholder meeting report:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140128467

__________________________________________________________________________________________________
BIG PHARMA AND POTENTIAL PARTNER DISCUSSION:


The Drug industry's influence over research:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142652537

How the Alzheimer’s Cabal Thwarted Research for 30 years! (from Biostockclub)
https://www.statnews.com/2019/06/25/alzheimers-cabal-thwarted-progress-toward-cure/

Why Big Pharma's plaque attack trials failed:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149743210

How Alzheimer’s Cabal Thwarted Research si30 years! (from Biostockclub)
https://www.statnews.com/2019/06/25/alzheimers-cabal-thwarted-progress-toward-cure/

Commonly prescribed drugs are tied to nearly 50% higher dementia risk in older adults, study says (from kevli33).
https://www.cnn.com/2019/06/24/health/dementia-risk-drug-study/index.html

Is the Alzheimer's epidemic the result of bad pharma and bad psychiatry?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142358853

Eisai trying to emulate Anavex approach:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149720753
Eisai PR not behind paywall 6/13/18:
https://www.eisai.com/news/2018/news201847.html

The “next wave” of BP’s being incubated now, in the form of small, smart, faster biotechs! 4/23/19 article:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148381829

Merck and 21st Century Medicine
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148109429

Merck and the Canadians team up:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148108335
https://www.eurekalert.org/pub_releases/2017-03/mu-npt031717.php

Roche and Genentech - a case study:
https://knowledge.wharton.upenn.edu/article/anatomy-of-a-merger-hostile-deals-become-friendly-in-the-end-right/

Why modern medicine is like the medieval church:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146539971

Below is a link to a 6-part article that shines a bright light on big pharma's influence in the market, research and fake news... rather revealing! (from basparks79)
https://articles.mercola.com/sites/articles/archive/2017/12/27/drug-safety-media-shaped-by-big-pharma.aspx

BIIB's problem with their Alzheimer's trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144801572

Bayer also bailing on R&D:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145174145

Why did Big Pharma bail on Alzheimer's trials early 2018? Possible Answer:
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM596728.pdf
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205259
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145214094
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145215823
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145214295

“Watch: How did the amyloid hypothesis go from promising to perilous in the search for Alzheimer’s treatments?”
By Damian Garde @damiangarde and Alex Hogan @hoganalex
May 21, 2019
(from kevli33)
https://www.statnews.com/2019/05/21/alzheimers-disease-amyloid-hypothesis-history/

(see also MS section above)

______________________________________________________________________________________________
TRIAL PROCEDURE:

Reasons why it's good to be running trials in Australia...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140883830
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147033379

Data from another trial can be used to support an approval:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148906992

Japan:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148770129
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148770231

Multi-regional clinical trials and global drug development - 2016 changes in trial technique:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149099281
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149099929
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149100322

Procedure and implications of post trial access to drugs:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149179546
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149180303


U.S. FDA: 07/17/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149960864

AUSTRALIA'S TGA: 07/08/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149809185

OTHER COUNTRIES-General Comments: 06/02/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149156871

_____________________________________________________________________________________________
LINKS TO OTHER SECTIONS:

MOA and MEDICAL SCIENCE DISCUSSION 07/08/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149887703

IP Protection:07/12/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149887580

Elder Care Crisis:07/12/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149887464

The People of Anavex 07/12/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149887343

Genetic issues- sex and more 07/12/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149887394

Anavex Partners 06/02/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149887780

3-71 Discussion 07/09/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149817651

AVXL -The Stock and the Market 07/12/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149887646

PRESS AND THIRD PARTY 07/08/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149784141

GUT and BRAIN - barrier and permeability 07/08/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149779986

SLEEP 07/08/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149786654